GVK Biosciences, a contract research organization, has commissioned its new clinical pharmacology unit (CPU) in Ahmedabad. The facility adds 110 beds to the company's existing capacity of 144 beds and will conduct a range of tests on healthy volunteers.
Ahmedabad was the most preferred and logical destination for expansion considering the volunteer pool accessibility and proximity to about 10 clinical research organizations and leading pharma companies. With 3 clinical wards and 110 beds, the unit is state-of-the-art and designed to suit all regulatory requirements. It also has special housing facilities for female volunteers. Key features of this unit include access to special population like young women, post-menopausal women, diseased population and access to about 12,000 healthy volunteers.
The company is a top service provider of bioequivalence studies to generic pharma companies globally. The clinical pharmacology unit, operational from 2004 in Hyderabad, has undergone several international audits, inspections and has key accreditations to its credit including the US FDA, DCG(I), ANVISA (Brazil), AFSSAPS (France), WHO and the Ministry of Health, Turkey. In addition to the healthy volunteer population, the Ahmedabad facility gives access to diseased population in psychiatry, metabolism, cardiovascular, neurology etc.
This new clinical pharmacology unit will aid faster recruitment solutions to our customers. The facility has been audited by the DCGI and we have initiated our first study at the Ahmedabad, said Manni Kantipudi, president, GVK Biosciences.
